News & Trends - MedTech & Diagnostics
The big themes impacting ASX-listed healthcare companies
MedTech News: The COVID-19 pandemic has significantly impacted many ASX-listed healthcare companies, such as ResMed, Fisher and Paykel Healthcare, Sonic Healthcare and CSL.
Sonic Healthcare and Australian Clinical Labs have benefitted as COVID-19 testing has surged during the last couple of years.
That said, the past three years hasn’t been an unexpected gain for all. Supply chain challenges have impacted companies like ResMed, while lockdowns have prevented CSL from executing its flagship product.
In 2023, the Australian healthcare sector is facing two headwinds. The short-term headwind is the Chinese reopening. The long-term headwind is the impact inflation has on production, according to Citi’s Australian health analysts.
The top three ASX healthcare companies – CSL, ResMed and Fisher and Paykel Healthcare – have pricing power and resilient demand which should offset the negative impact of inflation and/or a potential recession, at least to some degree, according to the analysts.
CSL is focused on plasma collection, recovery in Vifor sales post-COVID, the Argenx CIDP P3 clinical trial data in Q2 2023, and the transition to the Terumo plasma collection devices.
In the case of ResMed, the company continues to benefit from the Philips CPAP medical device recall for sleep aponea. ResMed believes that it will have the capacity to supply the entire market once the availability of semiconductors improves, potentially reducing the likelihood of a quick return to market by Philips.
On the other hand, Ramsay Health Care and Integral Diagnostics continue to face the uncertainty around COVID-19, workforce challenges and the pace of recovery of their businesses. Cochlear could also be hit if the pace and severity of China’s COVID-19 reopening changes dramatically.
In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Pharmaceuticals
Will the new PBS campaign pressure the government to act?
Pharma News: The medicines industry is ramping up its campaign to slash delays in patient access to new and innovative […]
MoreNews & Trends - MedTech & Diagnostics
Private hospitals struggle despite surge in admissions: Financial crisis worsens as inflation outpaces benefits
MedTech & Diagnostics News: Private hospital admissions are on the rise, but this uptick is not enough to counter the […]
MoreDigital & Innovation
Health sector and government under scrutiny: Record data breaches expose millions
Digital & Innovation: The national privacy regulator has raised alarm over escalating threats, reporting a record surge in data breach notifications. […]
MoreMedical and Science
Diabetes research funding plummets by 35%: Consultation launched to reverse decline
Medical & Science: Australia’s diabetes crisis is deepening, with calls for urgent action growing louder. The Standing Committee on Health, […]
More